ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2020
Nonremission and Recurrent Tumor-Induced Osteomalacia: A Retrospective Study.
Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Clinical characteristics of pediatric tumor-induced osteomalacia: a systematic review and individual patient data analysis.Frontiers in endocrinology · 2026Pooled it
- Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series.Endocrine · 2022Pooled it
- Surgical Treatment of Tumor-Induced Osteomalacia With Causative Tumors Affecting the Long Bones.Orthopaedic surgery · 2026Article
- Tumor-induced osteomalacia caused by fibroblast growth factor 23 excess : Delayed diagnosis resulting from overlooked hypophosphatemia-A case report.Wiener klinische Wochenschrift · 2026Article
- Recent research progress on the etiology and pathogenesis of tumor-induced osteomalacia: A review.Journal of bone oncology · 2026Review
- Article
- Clinical characteristics of tumor-induced osteomalacia lesions in the neurocranium and intracranial structures.Orphanet journal of rare diseases · 2026Article
- A Case of Tumor-Induced Osteomalacia Masked by Parathyroid Carcinoma.Journal of clinical medicine · 2026Article
- Article
- Surgical Treatment for Osteomalacia Induced by Causative Tumor in the Knee Joint Region: A Single-Center Retrospective Clinical Study Over 10 Years.Orthopaedic surgery · 2025Article
- A nomogram for predicting surgery outcome of tumor-induced osteomalacia: a case-control study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Serum Phosphorus Is a Fast and Highly Sensitive Marker Predictive of a Complete Cure of Tumor-Induced Osteomalacia.Journal of clinical medicine · 2025Article
- Surgical treatment as a key determinant of outcome in phosphaturic mesenchymal tumors of the bone and soft tissue: a systematic review and case series.EFORT open reviews · 2025Article
- Challenges in Evaluation and Management in Tumor-Induced Osteomalacia: A Retrospective Institutional and Literature-Based Scoping Review in Korean Patients.Journal of bone metabolism · 2025Article
- X-linked hypophosphatemia and tumor-induced osteomalacia: a narrative review and expert opinion on the diagnostic and therapeutic challenges in the era of burosumab.Orphanet journal of rare diseases · 2025Review
- Postoperative outcome and clinical management of tumor-induced osteomalacia: a single-center retrospective cohort study on 117 patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Oncogenic rickets diagnosed at age 8 and the risk of persistent rickets: a rare case of pediatric-onset tumor-induced osteomalacia.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Unmasking Skull Base Phosphaturic Mesenchymal Tumors: A Rare and Treatable Cause of Tumor-Induced Osteomalacia.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Successful cryoablation for a phosphaturic mesenchymal tumor in the maxilla causing tumor-induced osteomalacia: a case report.Archives of osteoporosis · 2025Article
- Orthopedic surgical treatment of osteomalacia induced by culprit soft tissue tumor in the hip region: a single-center retrospective study.BMC musculoskeletal disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treated with surgery in a tertiary hospital. TIO was established based on a pathologic examination or the reversion of hypophosphatemia. Refractory TIO patients consisted of those with nonremission or recurrent hypophosphatemia after surgery. A total of 230 patients were confirmed as having TIO. After primary surgery, 26 (11.3%) cases persisted, and 16 (7.0%) cases recurred. The overall refractory rate was 18.3%. The median time of recurrence was 33 months. Compared with patients in the recovery group, patients in the refractory group were more likely to be female (59.5% versus 41.0%, p = .029) and have a lower serum phosphate level (0.44 ± 0.13 versus 0.50 ± 0.11 mmol/L, p = .002). The refractory rate was lowest in head/neck tumors (7.5%) and highest in spine tumors (77.8%). Regarding the tissue involved of tumor location, the refractory rate was higher in tumors involving bone than tumors involving soft tissue (32.7% versus 7.0%, p < .001). The outcomes of malignant tumors were worse than those of benign tumors (p < .001): nonremission rate, 21.4% versus 9.7%; recurrence rate, 28.6% versus 6.5%. In the multivariate regression analysis, female sex, spine tumors, bone tissue-involved tumors, malignancy, and low preoperation serum phosphorus levels were identified as risk factors for refractory outcomes. High preoperative fibroblast growth factor 23 (FGF23) levels were also associated with refractory after adjusting for involving tissue and tumor malignancy. In summary, we are the first to report the rate and clinical characteristics of refractory TIO in a large cohort. For patients with multiple risk factors, especially spine tumors, clinical practitioners should be aware of a poor surgical prognosis. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.